What is the difference between a cardiac biomarker of necrosis and one of wall stress?

Necrosis markers such as troponin and CK-MB leak from heart-muscle cells when they are damaged, so they indicate cell injury; wall-stress markers such as BNP and NT-proBNP are actively secreted in response to ventricular stretch, so they indicate haemodynamic strain rather than cell death.

Why is troponin considered the central cardiac biomarker?

Troponin is a structural protein largely specific to cardiac muscle, and modern high-sensitivity assays measure it precisely at very low concentrations, which is why the Universal Definition of Myocardial Infarction places troponin above the 99th-percentile reference limit at the centre of the biochemical definition of myocardial injury.

Cardiac Biomarkers and Myocardial Injury

Cardiac biomarkers are circulating molecules whose blood concentrations rise when the heart is injured, stressed, or strained, and they form the biochemical backbone of how myocardial injury is detected and characterised in the laboratory. This area orients the reader to the major classes of cardiac markers, what each one reflects biochemically, and how the field has moved from enzyme-release markers toward highly sensitive, structurally specific assays.

Najít téma v PaperMindJiž brzyFind papers & topics

Tools & resources

Stáhnout prezentaci

Learn & explore

VideoJiž brzy

Definition

Cardiac biomarkers are measurable molecules released into the circulation from cardiomyocytes (or produced in response to cardiac stress) whose concentration reflects myocardial injury, necrosis, wall stress, or associated processes, and which are quantified by laboratory immunoassays to characterise the state of the heart.

Scope

The area surveys the principal cardiac biomarkers as analytes of clinical biochemistry: troponins and high-sensitivity troponin assays, the natriuretic peptides, the older necrosis markers myoglobin and creatine kinase-MB, ischemia-modified albumin, and D-dimer as a coagulation marker relevant to acute cardiovascular presentations. It frames them by their molecular origin, release kinetics, and analytical performance rather than by diagnostic algorithms, and it treats myocardial injury through the lens of the Universal Definition of Myocardial Infarction, which positions troponin elevation at the centre of the biochemical definition.

Sub-topics

Core questions

What molecular event does each cardiac biomarker actually report — necrosis, wall stress, ischaemia, or coagulation activation?
How do release kinetics (rise, peak, and clearance) shape the analytical window in which a marker is informative?
What does 'high-sensitivity' mean analytically, and how does it change the interpretation of low-level troponin elevations?
How is myocardial injury defined biochemically, and how does it differ from myocardial infarction?
What non-cardiac and pre-analytical factors influence biomarker concentrations and their reference limits?

Key concepts

Myocardial injury versus myocardial infarction
99th-percentile upper reference limit
Release kinetics and the diagnostic window
Analytical sensitivity and assay imprecision (CV at the URL)
Marker specificity for cardiac tissue
Wall-stress markers versus necrosis markers
Serial sampling and the delta (change) concept
Pre-analytical and biological variation

Mechanisms

Cardiac biomarkers report distinct biological events. Necrosis markers (cardiac troponins, creatine kinase-MB, myoglobin) leak from cardiomyocytes when membrane integrity is lost; troponins, as structural contractile-apparatus proteins largely restricted to the heart, combine high cardiac specificity with sustained release, whereas myoglobin and CK-MB appear and clear faster and are less specific. Wall-stress markers — B-type natriuretic peptide and its N-terminal prohormone fragment — are synthesised and secreted by myocytes in response to ventricular stretch and pressure, so they index haemodynamic strain rather than cell death. Ischemia-modified albumin reflects a proposed conformational change in albumin under ischaemic conditions, and D-dimer marks activation of coagulation and fibrinolysis. The shift to high-sensitivity troponin assays lowered the limit of detection enough to quantify troponin in most healthy individuals, sharpening the definition of injury around the 99th-percentile reference limit and serial change.

Clinical relevance

Cardiac biomarkers underpin how myocardial injury is recognised and described in laboratory medicine, and understanding what each marker reflects is part of interpreting cardiac investigations critically. This area is a reference orientation to the analytes and their biology; it explains how biochemical evidence of cardiac injury is generated and is not a source of diagnostic thresholds or treatment decisions for individual patients.

Epidemiology

Acute coronary syndromes and heart failure are among the most frequent reasons for acute cardiovascular evaluation worldwide, and cardiac biomarkers are among the most commonly ordered laboratory tests in emergency and cardiology settings. The Universal Definition of Myocardial Infarction frameworks have progressively standardised how troponin-based injury is reported across health systems.

Evidence & guidelines

The Fourth Universal Definition of Myocardial Infarction (Thygesen et al., 2018) sets the consensus framework that places troponin above the 99th-percentile reference limit at the centre of the biochemical definition of myocardial injury and infarction. European Society of Cardiology guidance on non-ST-elevation acute coronary syndromes (Roffi et al., 2015) and reviews of biomarkers in heart failure (Braunwald, 2008) describe how the major marker classes are positioned in cardiovascular evaluation.

History

The biochemical detection of myocardial injury began with non-specific enzymes such as aspartate aminotransferase and lactate dehydrogenase, advanced to the more cardiac-oriented creatine kinase-MB, and was transformed by the introduction of cardiac troponin assays in the 1990s, which offered far greater cardiac specificity. Successive Universal Definition of Myocardial Infarction documents then formalised troponin's central role, and high-sensitivity assays in the 2010s refined the resolution at which injury could be measured.

Debates

Where should the boundary between physiological and pathological troponin lie?: High-sensitivity assays detect troponin in most healthy people, so distinguishing chronic low-level elevation from acute injury depends on the 99th-percentile limit and on serial change rather than a single positive/negative cut-off, and the interpretation of small elevations remains an active methodological discussion.

Key figures

Kristian Thygesen
Allan S. Jaffe
Eugene Braunwald
Fred S. Apple

Seminal works

thygesen-2019
braunwald-2008
apple-2003

Frequently asked questions

What is the difference between a cardiac biomarker of necrosis and one of wall stress?: Necrosis markers such as troponin and CK-MB leak from heart-muscle cells when they are damaged, so they indicate cell injury; wall-stress markers such as BNP and NT-proBNP are actively secreted in response to ventricular stretch, so they indicate haemodynamic strain rather than cell death.
Why is troponin considered the central cardiac biomarker?: Troponin is a structural protein largely specific to cardiac muscle, and modern high-sensitivity assays measure it precisely at very low concentrations, which is why the Universal Definition of Myocardial Infarction places troponin above the 99th-percentile reference limit at the centre of the biochemical definition of myocardial injury.